Enantioselective analysis of N-hydroxymexiletine glucuronide in human plasma for pharmacokinetic studies

Chirality

Volumn 11, Issue 2, 1999, Pages 85-90

  Lanchote, Vera Lucia ^a   Santos, Verônica Jorge ^a   Cesarino, Evandro José ^a   Dreossi, Sônia Aparecida Carvalho ^a   Mere Jr , Yussif ^b   Santos, Silvia Regina Cavani Jorge ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University of the State of São Paulo   (Brazil)

Author keywords

Enantioselectivity; HPLC; Mexiletine; N hydroxymexiletine glucuronide; Patient; Plasma

Indexed keywords

ACETYLCYSTEINE; BETA GLUCURONIDASE; METHANOL; MEXILETINE; N HYDROXYMEXILETINE GLUCURONIDE; PHTHALALDEHYDE; SULFATASE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CHAGAS DISEASE; CHIRALITY; CONTROLLED STUDY; DIASTEREOISOMER; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HYDROLYSIS; ENANTIOMER; HUMAN; PH; PLASMA; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANTI-ARRHYTHMIA AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROLYSIS; MEXILETINE; REPRODUCIBILITY OF RESULTS; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 0032894348     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1999)11:2<85::AID-CHIR1>3.0.CO;2-P     Document Type: Article

References (13)

1. Nation RL. Chirality in new drug development. Clinical pharmacokinetic considerations. Clin Pharm 1994;27:249-255.
2. Kroemer HK, Fromm MF, Eichelbaum M. Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and induction. Ther Drug Monit 1996;18:388-392.
3. Grech-Bélanger O, Turgeon J, Lalande M, Bélanger PM. Metahydroxymexiletine, a new metabolite of mexiletine. Isolation, characterization, and species differences in its formation. Drug Metab Dispos 1991;19:458-461.
4. Turgeon J, Paré JRJ, Lalande M, Grech-Bélanger O, Bélanger PM. Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination. Drug Metab Dispos 1992;20:762-769.
5. Abolfathi Z, Fiset C, Gilbert M, Moerike K, Bélanger PM, Turgeon J. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans. J Pharmacol Exp Ther 1993;266:1196-1201.
6. Grech-Bélanger O, Turgeon J, Gilbert M. Stereoselective disposition of mexiletine in man. Br J Clin Pharmacol 1986;21:481-487.
7. Knoche B, Gehrcke B, Konig WA, Wainer IW. Determination of the enantiomeric composition of mexiletine and its four hydroxylated metabolites in urine by enantioselective capillary gas chromatography. Chirality 1996;8:30-34.
8. Lanchote VL, Cesarino EJ, Santos VJ, Moraes Júnior AV, Zanardi AMT, Santos SRCJ. Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias. Eur J Drug Metab Pharmacokinet 1998; Forthcoming.
9. Bressolle F, Bromet-Petit M, Audran M. Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmaco-kinetics. J Chromatogr B, Biomed Appl 1996;686:3-10.
10. Turgeon J, Uprichard ACG, Bélanger PM, Harron DWG, Grech-Bélanger O. Resolution and electrophysiological effects of mexiletine enantiomers. J Pharm Pharmacol 1991;43:630-635.
11. Lanchote VL, Bonato PS, Dreossi SAC, Gonçalves PVB, Bertucci C. HPLC determination of mexiletine enantiomers in plasma using direct and indirect enantioselective separations. J Chromatogr B, Biomed Appl 1996;685:281-289.
12. Wright MR, Jamali F. Methods for the analysis of enantiomers of racemic drugs. Application to pharmacological and pharmacokinetic studies. Pharmacol Toxicol Methods 1993;29:1-9.
13. Ducharme J, Fernandez C, Gimenez F, Farinotti R. Critical issues in chiral drug analysis in biological fluids by high-performance liquid chromatography. J Chromatogr B, Biomed Appl 1996;686:65-75.